EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.

Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. J Hepatol. 2021 Nov 2:S0168-8278(21)02155-3. doi: 10.1016/j.jhep.2021.10.018.